SITC 2025

Stop by our booth to experience live demos of our newest technologies and discover how we are leveraging AI to advance precision medicine.

Tempus Lens

Quickly define detailed patient cohorts using natural language processing and transform complex criteria into actionable datasets. Explore unstructured clinical data and extract nuanced insights. With Lens, the power of Tempus data is at your fingertips.

A multi-omic immune profile score (IPS) stratifies real-world outcomes of microsatellite stable (MSS) advanced colorectal cancer patients treated with immune checkpoint inhibitors

First Author
Rossin Erbe, PhD (Tempus AI, Inc.), et al.

A novel multi-omic algorithm to predict real-world outcomes among patients with rare, advanced, solid cancers treated with off-label immune checkpoint inhibitors

First Author
Michelle Ting-Lin, MD (Tempus AI, Inc.), et al.

Impact of Androgen Receptor Mutations on Immune Infiltration in Castration Resistant Prostate Cancer

First Author
Fu Luo, PhD (Tempus AI, Inc.), et al.

MAIT Cell Abundance Within Tumors Are Associated with Key Clinical Characteristics Across Solid Tumors

First Author
Emon Elboudwarej, PhD (Tempus AI, Inc.), et al.

TargetR: Automated Multi-Omics Report Framework for Target Characterization and Validation of Immunotherapy and Targeted Therapy Candidates Across Cancers

First Author
Vincent M Perez, PhD (Tempus AI, Inc.), et al.

Ultrahigh Tumor Mutational Burden (TMB) Is Associated with Improved Survival Outcomes in Patients (Pts) Treated with Immune Checkpoint Inhibitors (ICIs)

First Author
Douglas B. Johnson, MD (Vanderbilt University Medical Center), et al.

Analysis of PRAME in advanced/metastatic solid tumors shows homogeneous expression, and stability between lesions, across treatment lines, and upon exposure to checkpoint inhibitors